Bortezomib 2 mg Injection (Bortero) – Oncology Export Supplier

Bortezomib 2 mg injection is a prescription-only oncology injectable supplied as a lyophilized powder for reconstitution. Marketed under the brand name Bortero, this product contains Bortezomib, a proteasome inhibitor used within regulated hematological oncology treatment frameworks. Bortezomib 2 mg injection is manufactured for hospital and institutional use and is offered strictly for international export to licensed pharmaceutical distributors, hospitals, and cancer treatment centers. AmeriDrugs does not supply this product for retail sale or direct patient use.

Active Ingredient

• Bortezomib – 2 mg per vial
  Bortezomib is a dipeptidyl boronic acid derivative that inhibits the 26S proteasome and is used under approved oncology indications.

Therapeutic Use

From an informational and regulatory perspective, Bortezomib 2 mg injection is used in approved hematological oncology settings, including plasma cell disorders, as defined by regulatory authorities in the importing country. This information is provided solely for product identification and international trade clarity. AmeriDrugs does not provide medical advice, treatment protocols, or patient-level guidance related to Bortezomib 2 mg injection.

Dosage Form

• Sterile lyophilized powder for injection

• Single-use vial

• Intended for intravenous administration under professional supervision

• Preparation and administration decisions are determined exclusively by qualified healthcare professionals in accordance with local regulations

Quality & Manufacturing Standards

Bortezomib 2 mg injection (Bortero) is manufactured in GMP-compliant facilities operating under validated pharmaceutical quality management systems. Manufacturing includes sterile processing, batch-wise quality control, and stability testing to ensure identity, strength, purity, and consistency aligned with international export standards for Bortezomib 2 mg injection.

Packaging Information

• Single-use vial containing 2 mg lyophilized bortezomib

• Secure pharmaceutical-grade vial with rubber stopper and flip-off seal

• Export-grade secondary packaging for international transport

• Labeling compliant with prescription injectable oncology medicine regulations

Target Buyers

This product is intended exclusively for supply to:

• Licensed pharmaceutical importers and distributors

• Hospitals and oncology treatment centers

• Government and private cancer care institutions

• Authorized healthcare procurement agencies

It is not intended for retail pharmacies, online consumer sales, or direct patient distribution.

Regulatory & Compliance Note

Bortezomib 2 mg injection (Bortero) is a prescription-only oncology injectable. Importation, storage, distribution, and use must comply with the pharmaceutical laws, injectable drug regulations, and oncology approvals of the destination country. Buyers are responsible for ensuring regulatory compliance within their jurisdiction. AmeriDrugs operates solely as an export-focused pharmaceutical supplier and does not promote Bortezomib 2 mg injection for self-medication or any non-regulated use.